Repligen (NASDAQ:RGEN) Trading 10.3% Higher – Should You Buy?

Repligen Corporation (NASDAQ:RGEN) shares traded up 10.3% on Thursday . The stock traded as high as $124.37 and last traded at $124.7720. 586,495 shares traded hands during mid-day trading, a decline of 39% from the average session volume of 955,606 shares. The stock had previously closed at $113.17.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Royal Bank Of Canada assumed coverage on shares of Repligen in a research report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 target price for the company. JPMorgan Chase & Co. dropped their target price on shares of Repligen from $180.00 to $165.00 and set an “overweight” rating for the company in a research report on Wednesday, May 6th. Jefferies Financial Group reissued a “hold” rating and issued a $142.00 target price on shares of Repligen in a research report on Tuesday, May 5th. HC Wainwright boosted their target price on shares of Repligen from $180.00 to $208.00 and gave the stock a “buy” rating in a research report on Monday, March 23rd. Finally, Canaccord Genuity Group dropped their target price on shares of Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a research report on Monday, April 20th. Two analysts have rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $166.15.

Repligen Stock Performance

The company has a quick ratio of 7.78, a current ratio of 9.20 and a debt-to-equity ratio of 0.26. The stock has a 50 day simple moving average of $117.74 and a 200 day simple moving average of $140.04. The company has a market capitalization of $7.12 billion, a price-to-earnings ratio of 140.10, a P/E/G ratio of 2.22 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.38 by $0.10. Repligen had a return on equity of 4.88% and a net margin of 6.73%.The company had revenue of $194.26 million during the quarter, compared to the consensus estimate of $192.05 million. During the same period in the previous year, the firm posted $0.39 earnings per share. Repligen’s quarterly revenue was up 14.8% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. As a group, analysts anticipate that Repligen Corporation will post 1.99 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Repligen

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Wealth Enhancement Advisory Services LLC boosted its stake in Repligen by 1.9% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 4,001 shares of the biotechnology company’s stock valued at $584,000 after acquiring an additional 75 shares during the period. NewEdge Wealth LLC boosted its stake in Repligen by 5.3% during the 4th quarter. NewEdge Wealth LLC now owns 1,492 shares of the biotechnology company’s stock valued at $244,000 after purchasing an additional 75 shares during the period. UMB Bank n.a. boosted its stake in Repligen by 13.8% during the 4th quarter. UMB Bank n.a. now owns 758 shares of the biotechnology company’s stock valued at $124,000 after purchasing an additional 92 shares during the period. CANADA LIFE ASSURANCE Co boosted its stake in Repligen by 0.3% during the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 36,599 shares of the biotechnology company’s stock valued at $4,542,000 after purchasing an additional 100 shares during the period. Finally, Coldstream Capital Management Inc. boosted its stake in Repligen by 5.3% during the 4th quarter. Coldstream Capital Management Inc. now owns 1,992 shares of the biotechnology company’s stock valued at $326,000 after purchasing an additional 101 shares during the period. 97.64% of the stock is currently owned by institutional investors and hedge funds.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.